The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse efanesoctocog alfa (Altuvoct®) through the basic healthcare package. This medicinal product can be used in certain patients with haemophilia A. This is a hereditary disorder in which the blood does not clot properly. The reason for this advice was the medicinal product being placed in what is known as the ‘lock procedure for expensive medicinal products’.
Venetoclax with obinutuzumab is intended for certain people with previously untreated leukaemia
Efanesoctocog alfa is the active substance; the brand name is Altuvoct®. The medicine is an injection.
The medicine can be used in people with haemophilia A, a hereditary disorder in which the blood does not clot properly. People with haemophilia A have a greater risk of haemorrhages, bruising, and continued bleeding in the perioperative setting. It is commoner in men than in women.
Advice of the National Health Care Institute on the reimbursement of efanesoctocog alfa
The National Health Care Institute advises the Minister of VWS to reimburse efanesoctocog alfa (Altuvoct®) from the basic healthcare package. The net price of the medicine may not exceed the net price of the standard treatment with products containing factor VIII.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Scientific Advisory Board (WAR) advises the National Health Care Institute when issuing a package advice. The final decision as to whether or not reimbursement from the basic healthcare package will take place lies with the Minister.
Explanation of the package lock procedure for expensive medicinal products
The minister has placed efanesoctocog alfa in the 'lock procedure for expensive medicinal products' for this indication. A medicinal product in this lock procedure will not be eligible for reimbursement from the basic healthcare package until:
- there is a positive package advice from the National Health Care Institute;
- there are arrangements and safeguards for appropriateness in place;
- price reductions have been successfully negotiated with the marketing authorisation holder.
For more information, see the page ‘Lock procedure for expensive medicinal products’.